The main purpose of the study was to determine the efficacy of CDP870 in treating RA signs/symptoms in patients who were partial responders to MTX. Other purposes were to show additional efficacy without increased toxicity and the immunogenic response to CDP870 during combined CDP870 and MTX therapy.
Read more: http://www.clinicaltrials.gov/ct2/show/NCT00544154?cond=%22Arthritis%22&lup_s=08/23/2013&lup_d=30
